Business Context and Reporting Period
This Form 8-K was filed by Hemispherx Biopharma, Inc. on December 16, 2015, reporting events occurring on December 15, 2015. The filing details the entry into a new material definitive agreement regarding an equity distribution program.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures. The primary financial metric disclosed is the commission structure for the new equity program:
- Commission Rate: 3.0% of the gross sales price of shares sold under the new agreement.
- Previous ATM Cap: Reduced to $0 for the prior agreement with Maxim Group LLC.
Material Changes
The Company executed the following material changes on December 15, 2015:
- New Equity Distribution Agreement: Entered into an "at-the-market" (ATM) offering agreement with Chardan Capital Markets, LLC to sell common stock.
- Termination of Prior ATM: Filed a Prospectus Supplement reducing the offering amount under the existing agreement with Maxim Group LLC to $0.
- Executive Compensation Waivers: CEO Dr. William A. Carter and President/CFO Thomas K. Equels waived rights to future incentive bonuses related to stock sales under ATM agreements to preserve cash.
Guidance, Outlook, and Risks
Management Commentary: The executive waivers were voluntarily provided to preserve cash and ensure the Company can meet its short-term commercialization goals. The Company retains the right to suspend or terminate the new Chardan agreement at any time and has no obligation to sell shares.
Risks and Contingencies: The filing notes that sales of shares are subject to market conditions and applicable securities laws. No specific financial guidance or forward-looking revenue projections are included in this report.
Investor Verification Checklist
- Verify the status of the Company's cash reserves and burn rate given the executive bonus waivers.
- Confirm the number of shares registered under Form S-3 (File No. 333-205228) available for the new ATM program.
- Monitor future 8-K filings for actual share sales and proceeds generated under the Chardan agreement.
- Review the full text of the Equity Distribution Agreement (Exhibit 10.1) for specific termination clauses and sales restrictions.